Global Conjugate Vaccine Market (2017 – 2022)

Updated On: 19 February, 2019 | No of Pages: 90-100 | Format: PDF | SKU: 201877
  • Report Description
  • Table of Content
  • Request Sample
  • Customize Report
  • Speak to Analyst
  • Enquire before purchase

The market for conjugate vaccines is expected to increase, owing to global awareness about the benefits of vaccination for the prevention of certain life-threatening diseases, growing initiatives for production of low-cost vaccines, and widespread routine vaccination programmes in emerging economies. The market will witness a steady growth, expanding at a compound annual growth rate (CAGR) of 11.7% during 2017-2022, to reach approximately USD 87.7 Bn by 2022.

Global Conjugate Vaccine Market (2017-2022)

Disease indication segment insights:

Pneumococcal conjugate vaccine (PCV) held the largest market share (24.66%) in 2017 owing to the widespread nature of pneumococcal disease. Also, the leading vaccine-preventable cause of death among children around the world is the pneumococcal disease. Global initiatives were undertaken to speed up the introduction of pneumococcal vaccinations in low-income countries through partnerships among countries, donors, academia, international organizations, and industries. Close on its heels, the diphtheria and tetanus toxoids and pertussis (DTP) conjugate vaccine occupied a share of 23% in 2017. The higher prevalence of respiratory diseases such as whooping cough, among both children and adults, have led to the increased adoption of DTP conjugate vaccines. Haemophilus influenzae type b (Hib) conjugate vaccines are expected to grow at the fastest rate during 2017–2022.

End user segment insights:

The adult segment registered higher market share than the paediatric segment because of an increase in awareness on conjugate vaccines for adults, over the years. Still, the penetration level for adult conjugate vaccines is comparatively lower, with the lowest being for PCVs. Hence, the growth potential is very high. The paediatric vaccines, on the other hand is a stable market and depends highly on the birth rates in each region. The vaccination programmes, especially taken up by global organizations such as the United Nations Educational, Scientific and Cultural Organization (UNESCO), have been successful in eradicating many such vaccine-preventable diseases.

Regional insights:

Asia-Pacific is the largest market for conjugate vaccines, which held a share of 42%, in 2017. The primary indicators of the potential for the vaccine market is the geriatric population in the region, especially in countries such as India and China. In turn, this has, encouraged market participants to increase spending on research and development (R&D) and distribution facilities in the these countries. North America is the second biggest market for conjugate vaccines, owing to the region’s widespread immunization programmes. The Middle East and Africa, and Latin America regions lack proper infrastructure and awareness of vaccine-preventable diseases, which are hindering market growth.

Companies covered:

  • GlaxoSmithKline
  • Pfizer Inc.
  • Merck & Co.
  • Novartis
  • Sanofi Pasteur
  • CSL Limited
  • Bharat Biotech International
  • Biological E Limited
  • Serum Institute of India         

Customizations available:

With the given market data, Research on Global Markets offers customizations according to specific needs. Write to us at support@researchonglobalmarkets.com, or connect with us here.

Estimated Delivery Time: Immediate Dispatch

Chapter 1. Executive summary

 

1.1. Market scope and segmentation

1.2. Key questions answered

1.3. Executive summary

 

Chapter 2. Global conjugate vaccine market – overview

 

2.1. Market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), geography-wise market revenue (USD Bn), and market attractiveness analysis

2.2. Market drivers

2.3. Market trends

2.4. Market challenges

2.5. Value chain analysis

2.6. Porter's five forces analysis

2.7. Segmentation based on disease indication (pneumococcal conugate vaccine (PCV), haemophilus influenzae type B (Hib) conjugate vaccine, diptheria, tetanus toxoids and pertussis (DTP) conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

2.8. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

 

Chapter 3. North America conjugate vaccine market

 

3.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

3.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

3.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

 

Chapter 4. Europe conjugate vaccine market

 

4.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

4.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

4.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

 

Chapter 5. Asia-Pacific conjugate vaccine market

 

5.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

5.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

5.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

 

Chapter 6. Latin America conjugate vaccine market

 

6.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

6.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

6.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

 

Chapter 7. The Middle East and Africa conjugate vaccine market

 

7.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

7.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

7.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

 

Chapter 8. Competitive landscape

 

8.1. GlaxoSmithKline

8.1.a. Company snapshot

8.1.b. Products/services

8.1.c. Major initiatives/highlights

8.1.d. Growth strategy

8.1.e. Geographical presence

8.1.f. Key numbers

Note: Similar information areas will be covered for the remaining competitors:

8.2. Pfizer Inc.

8.3. Merck & Co.

8.4. Novartis

8.5. Sanofi Pasteur

8.6. CSL Limited

8.7. Bharat Biotech International

8.8. Biological E Limited

8.9. Serum Institute of India

 

Chapter 9. Conclusion

9.1. Future outlook

 

Appendix

  1. List of tables
  2. Research methodology
  3. Assumptions
  4. About Netscribes Inc.

 

I agree to receiving communication from Research on Global Markets and Netscribes.

For customization of market research reports, fill out the form below, or write to us at support@researchonglobalmarkets.com.

I agree to receiving communication from Research on Global Markets and Netscribes.
I agree to receiving communication from Research on Global Markets and Netscribes.
I agree to receiving communication from Research on Global Markets and Netscribes.
$2,065.00 $2,950.00
For Research Assistance
+1-888-831-3350 (US Toll Free)


Loading...
Ready for Christmas?
Get a magic promo code on your email!